Processa Pharmaceuticals aims to develop products where existing clinical evidence of efficacy already exists in the targeted unmet medical need condition with the drug itself or a drug with very similar pharmacology The Processa process focuses on the advancement of drugs that are ready for clinical development or have minimal pre-IND enabling studies to complete … Continue reading “Processa Pharmaceuticals Inc. (NASDAQ: PCSA) is “One to Watch””
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company focused on the development of drug products for patients with high unmet medical need conditions or no alternative treatment options, today announced the pricing of an underwritten public offering of 4,800,000 shares of common stock for a price to the public of $4.00 per share. Processa expects … Continue reading “NetworkNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Pricing of $19.2M Public Offering, Nasdaq Uplisting”
Investment Considerations Processa Pharmaceuticals aims to develop products where existing clinical evidence of efficacy already exists in the targeted unmet medical need condition with the drug itself or a drug with very similar pharmacology. The Processa process focuses on the advancement of drugs that are ready for clinical development or have minimal pre-IND enabling studies … Continue reading “Processa Pharmaceuticals Inc. (NASDAQ: PCSA)”
Processa Pharmaceuticals (OTCQB: PCSA), today announced its entry into a contingent precedent exclusive licensing agreement with Elion Oncology Inc. to develop, manufacture and commercialize eniluracil (“PCS6422”) globally. According to the update, PCS6422 is an oral drug designed to be administered with fluoropyrimidine cancer drugs (i.e., “capecitabine,” “5-FU”) in order to decrease their breakdown to inactive … Continue reading “NetworkNewsBreaks – Processa Pharmaceuticals Inc. (PCSA) Enters Exclusive Agreement to Expand Pipeline, Oncology Involvement”
Processa Pharmaceuticals (OTC: PCSA) recently announced that the U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug Designation to its leading clinical compound, PCS499, to treat Necrobiosis Lipoidica (“NL”). Presently, there is no FDA approved treatment for NL and no known biotech or pharma companies are currently developing a drug for NL. “We are … Continue reading “NetworkNewsBreaks – Processa Pharmaceuticals, Inc.’s (PCSA) PCS499 Receives Orphan Drug Designation from FDA to Treat Necrobiosis Lipoidica”
Processa Pharmaceuticals, Inc. (OTC: PCSA) was founded in 2017 in Hanover, Maryland, with a mission to develop products that can improve the survival and/or quality of life for patients who have a high unmet medical need. The company acquired the assets of Promet Therapeutics, LLC in October of 2017 and has assembled a proven regulatory science product … Continue reading “Processa Pharmaceuticals, Inc. (PCSA) Starts Presentation at the 8th Annual LD Micro Invitational”
Processa Pharmaceuticals (OTC: PCSA) (formerly Heatwurx, Inc.) was founded with a mission to develop products that can improve the survival and/or quality of life for patients who have a high unmet medical need. The Processa team are experts in developing drug products from IND-enabling studies to NDA submission. The company’s combined scientific, development and regulatory … Continue reading “Processa Pharmaceuticals, Inc. (PCSA) Starts Presentation at LD Micro Main Event”
